A Phase 1/2 Study of CLIO-8221 in Patients With Advanced Solid Tumors
Callio Therapeutics
Summary
The study will be conducted in 2 phases: Phase 1: Dose-escalation and Dose Level Expansion, Phase 1 will determine the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE). Phase 2: Tumor-Specific Expansions with Dose Optimization, Phase 2 will further evaluate CLIO-8221 in tumor-specific expansion cohorts to optimize dosing and assess preliminary efficacy.
Description
Phase 1: Dose-escalation and Dose Level Expansion. Dose escalation safety data will be reviewed by a Safety Monitoring Committee (SMC) to guide dosing decisions. Backfill enrollment may be used to further characterize safety, PK/PD, and antitumor activity. Phase 2: Tumor-Specific Expansions with Dose Optimization. Phase 2 will further evaluate CLIO-8221 in tumor-specific expansion cohorts to optimize dosing and assess preliminary efficacy. Safety, tolerability, PK/PD, and response data will support selection of the recommended Phase 2 dose (RP2D) for further development.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Patients with advanced solid tumors * Patients must have metastatic or unresectable disease not suitable for further local treatment and should have received prior beneficial therapies unless ineligible, unwilling, or lacking access. * LVEF ≥50% by echocardiogram (ECHO) or multigated acquisition (MUGA) scan. * An Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1 * Measurable disease per RECIST version 1.1 at baseline Exclusion Criteria: * Prior anti-tumor treatment with an ATRi. * Prior or concurrent malignancy whose natural history or treatm…
Interventions
- DrugCLIO-8221
intravenous (IV) infusion
Locations (11)
- DFCIBoston, Massachusetts
- Sarah Cannon Research Institute 335 24th Avenue North, Suite 400Nashville, Tennessee
- MD Anderson Cancer CenterHouston, Texas
- START San AntonioSan Antonio, Texas
- START MountainWest Valley City, Utah
- Scientia Clinical ResearchRandwick, New South Wales